Last reviewed · How we verify
Montelukast Oral Granules (OG)
Montelukast Oral Granules (OG) is a Leukotriene receptor antagonist Small molecule drug developed by Organon and Co. It is currently in Phase 3 development for Asthma (prophylaxis and chronic treatment), Allergic rhinitis, Exercise-induced bronchoconstriction.
Montelukast blocks cysteinyl leukotriene receptors (CysLT1) on airway and inflammatory cells, preventing leukotriene-mediated bronchoconstriction and inflammation.
Montelukast blocks cysteinyl leukotriene receptors (CysLT1) on airway and inflammatory cells, preventing leukotriene-mediated bronchoconstriction and inflammation. Used for Asthma (prophylaxis and chronic treatment), Allergic rhinitis, Exercise-induced bronchoconstriction.
At a glance
| Generic name | Montelukast Oral Granules (OG) |
|---|---|
| Sponsor | Organon and Co |
| Drug class | Leukotriene receptor antagonist |
| Target | CysLT1 receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Immunology |
| Phase | Phase 3 |
Mechanism of action
Montelukast is a selective antagonist of the cysteinyl leukotriene type-1 (CysLT1) receptor. Leukotrienes are inflammatory mediators released by mast cells and eosinophils that cause airway constriction, mucus secretion, and eosinophil recruitment. By blocking these receptors, montelukast reduces airway inflammation and improves airflow in asthma and allergic rhinitis.
Approved indications
- Asthma (prophylaxis and chronic treatment)
- Allergic rhinitis
- Exercise-induced bronchoconstriction
Common side effects
- Headache
- Pharyngitis
- Diarrhea
- Nausea
- Abdominal pain
Key clinical trials
- Study of the Safety and Pharmacokinetics of Montelukast (MK-0476) in the Treatment of Japanese Pediatric Participants With Perennial Allergic Rhinitis (MK-0476-520) (PHASE3)
- A Study of Montelukast (MK-0476) Compared With Fluticasone in Pediatric Participants With Chronic Asthma (MK-0476-303) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Montelukast Oral Granules (OG) CI brief — competitive landscape report
- Montelukast Oral Granules (OG) updates RSS · CI watch RSS
- Organon and Co portfolio CI
Frequently asked questions about Montelukast Oral Granules (OG)
What is Montelukast Oral Granules (OG)?
How does Montelukast Oral Granules (OG) work?
What is Montelukast Oral Granules (OG) used for?
Who makes Montelukast Oral Granules (OG)?
What drug class is Montelukast Oral Granules (OG) in?
What development phase is Montelukast Oral Granules (OG) in?
What are the side effects of Montelukast Oral Granules (OG)?
What does Montelukast Oral Granules (OG) target?
Related
- Drug class: All Leukotriene receptor antagonist drugs
- Target: All drugs targeting CysLT1 receptor
- Manufacturer: Organon and Co — full pipeline
- Therapeutic area: All drugs in Respiratory / Immunology
- Indication: Drugs for Asthma (prophylaxis and chronic treatment)
- Indication: Drugs for Allergic rhinitis
- Indication: Drugs for Exercise-induced bronchoconstriction
- Compare: Montelukast Oral Granules (OG) vs similar drugs
- Pricing: Montelukast Oral Granules (OG) cost, discount & access